双歧杆菌三联活菌联合莫沙必利对慢性功能性便秘患者便秘症状、胃肠功能的影响分析

Analysis of the effect of live combined bifidobacterium,lactobacillus and enterococcus combined with mosapride on constipation symptoms and gastrointestinal function in patients with chronic functional constipation

目的分析双歧杆菌三联活菌联合莫沙必利对慢性功能性便秘患者便秘症状、胃肠功能的影响。方法80例慢性功能性便秘患者,按随机数字表法分为对照组和研究组,每组40例。对照组给予莫沙必利治疗,研究组在对照组基础上采用双歧杆菌三联活菌治疗。比较两组治疗前后便秘症状评分、胃肠功能、生活质量评分及不良反应发生情况。结果治疗前,两组排便次数、排便困难、排便疼痛及排便不尽感评分比较,差异无统计学意义(P>0.05);治疗后,研究组排便次数、排便困难、排便疼痛及排便不尽感评分分别为(2.53±0.20)、(1.70±0.24)、(1.33±0.22)、(1.51±0.22)分,低于对照组的(3.44±0.29)、(2.11±0.31)、(1.75±0.26)、(1.75±0.19)分,差异具有统计学意义(P<0.05)。治疗前,两组胃泌素(GAS)、促胃动素(MTL)水平比较,差异无统计学意义(P>0.05);治疗后,研究组GAS(37.68±3.51)ng/L、MLT(236.35±28.21)ng/L高于对照组的(28.19±2.85)、(212.55±25.50)ng/L,差异具有统计学意义(P<0.05)。研究组不良反应发生率为7.50%,与对照组的10.00%比较,差异无统计学意义(P>0.05)。治疗前,两组生活质量评分比较,差异无统计学意义(P>0.05);治疗后,研究组生活质量评分(51.24±2.52)分低于对照组的(60.75±2.23)分,差异具有统计学意义(P<0.05)。结论双歧杆菌三联活菌联合莫沙必利治疗慢性功能性便秘,可有效改善患者的便秘症状,恢复其正常胃肠功能,且不良反应较少,治疗安全性较高,值得临床推广。

Objective To analyze the effect of live combined bifidobacterium,lactobacillus and enterococcus combined with mosapride on constipation symptoms and gastrointestinal function in patients with chronic functional constipation.Methods A total of 80 patients with chronic functional constipation were randomly divided into the control group and the research group,with 40 patients in each group.The control group was treated with mosapride,and the research group was treated with live combined bifidobacterium,lactobacillus and enterococcus on the basis of the control group.The scores of constipation symptoms,gastrointestinal function,quality of life score before and after treatment,and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference between the two groups in terms of defecation frequency,defecation difficulty,defecation pain and defecation dissatisfaction scores(P>0.05).After treatment,the scores of defecation frequency,defecation difficulty,defecation pain and discomfort in the research group were(2.53±0.20),(1.70±0.24),(1.33±0.22)and(1.51±0.22)points,which were lower than(3.44±0.29),(2.11±0.31),(1.75±0.26)and(1.75±0.19)points in the control group,and the differences were all statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of gastrin(GAS)and motilin(MTL)between the two groups(P>0.05).After treatment,the GAS(37.68±3.51)ng/L and MLT(236.35±28.21)ng/L in the research group were higher than(28.19±2.85)and(212.55±25.50)ng/L in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the research group was 7.50%,and the difference was not statistically significant when compared with 10.00%in the control group(P>0.05).Before treatment,there was no statistically significant difference in quality of life scores between the two groups(P>0.05).After treatment,the quality of life score(51.24±2.52)points of the research group was lower than(60.75±2.23)points of the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment of chronic functional constipation with live combined bifidobacterium,lactobacillus and enterococcus combined with mosapride can effectively improve patients’constipation symptoms and restore their gastrointestinal function with fewer adverse reactions and higher therapeutic safety,which is worthy of clinical promotion.